Compare CAAS & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | NYXH |
|---|---|---|
| Founded | N/A | 2009 |
| Country | China | Belgium |
| Employees | 4812 | N/A |
| Industry | Auto Parts:O.E.M. | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.7M | 126.0M |
| IPO Year | 2025 | 2021 |
| Metric | CAAS | NYXH |
|---|---|---|
| Price | $4.67 | $1.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 31.3K | ★ 369.2K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.87 | $1.26 |
| 52 Week High | $5.15 | $8.59 |
| Indicator | CAAS | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 23.76 |
| Support Level | $4.12 | N/A |
| Resistance Level | $4.75 | $3.43 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 81.58 | 6.11 |
China Automotive Systems Inc is a holding company. The firm, through its subsidiary, is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series of power steering models, including rack and pinion power steering, integral power steering, electronic power steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.